Lycia Therapeutics, Inc. LYCA

We are a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases. By leveraging our proprietary LYTAC (Lysosomal Targeting Chimera) platform, we have developed a pipeline of therapeutic candidates with the potential to provide deep and durable elimination of extracellular proteins that are inadequately addressed by currently available therapies. We are seeking to advance these therapeutic candidates through a streamlined clinical development strategy designed to generate early proof of concept, including Phase 1 pharmacodynamic and biomarker data, to assess target modulation and inform progression into later-stage clinical development. Our immunoglobulin E (IgE) portfolio consists of LCA-0061 and LCA-0062, which are both designed with an aim to efficiently degrade IgE for the treatment of allergic diseases, including food allergy. We are conducting a Phase 1 clinical trial of LCA-0061 in participants with elevated IgE, including patients with food allergy. Preliminary data from our first cohort of healthy atopic participants treated with a single 70 mg subcutaneous (SC) dose of LCA-0061 showed rapid, deep and sustained reduction in total and free IgE. We believe the initial LCA-0061 clinical data supports a differentiated profile from IgE blockers and provides initial human proof-of-mechanism for the LYTAC platform. We expect additional data in healthy participants with elevated IgE and food allergy patients in . LCA-0062, our fast-follower IgE program, is currently in Investigational New Drug (IND)-enabling activities, and, if we receive regulatory clearance, we intend to initiate a Phase 1 clinical trial and expect to receive initial data in . We are also advancing our Graves’ disease program, LCA-0321, which is designed with an aim to selectively degrade thyroid-stimulating hormone receptor (TSHR) autoantibodies (also known as thyrotropin receptor antibodies or TRAbs), the pathogenic drivers of Graves’ disease. We are conducting a Phase 1 clinical trial of LCA-0321 in patients with Graves’ disease, and we expect initial data in . --- We were incorporated under the laws of the State of Delaware on October 24, 2019, under the name Lycia Therapeutics, Inc. Our principal executive offices are located at 400 East Jamie Court, Suite 200, South San Francisco, California 94080, and our telephone number is (650) 392-3357. Our website address is https://www.lyciatx.com.

开盘与收盘涨幅为示例输入（非预测），请按自己的情景修改。散户通常很难按发行价获配。

• 价格区间可能在路演期间调整，最终以 424B4 定价为准；发行可能推迟或撤回。
• 开盘价常与发行价差距很大；锁定期到期后可能有集中卖出。

本页不构成申购建议，不评分、不给申购结论、不给新股预估上市价。